Chronic Lymphocytic Leukemia Management

Introduction to CLL Management

The American Society of Hematology recommends careful evaluation and monitoring of CLL patients with decreased white blood cell counts, but does not necessarily indicate immediate intervention if the patient is asymptomatic 1

Regular follow-up with blood counts every 3-12 months depending on disease dynamics is recommended 5
Complete blood count with differential to assess all cell lines is essential in evaluating a CLL patient with a decreased white blood cell count 1
Evaluation for signs of infection, assessment for disease progression or transformation, and review of current medications that might cause myelosuppression are crucial 1

The European Society for Medical Oncology suggests that if WBC decrease is mild and patient is asymptomatic, continue regular monitoring with CBC every 1-3 months 1
If patient is on active CLL treatment, assess if WBC decrease is an expected treatment effect, and consider dose adjustment of current therapy if appropriate 1
If patient has signs of infection, prompt evaluation with cultures and empiric antibiotics as needed, and consider G-CSF for severe neutropenia with infection 1
If patient has significant neutropenia (ANC <1.0 × 10^9/L), consider initiating CLL treatment if previously untreated, and for patients on treatment, dose modification may be required 3

Antibiotic prophylaxis may be considered in high-risk patients, according to the Infectious Diseases Society of America 2
Pneumocystis prophylaxis with co-trimoxazole during treatment with purine analogs or bendamustine is recommended 5
Pneumococcal and seasonal influenza vaccination is recommended in early-stage CLL, as suggested by the Centers for Disease Control and Prevention 5

Consider immunoglobulin replacement therapy if patient has severe hypogammaglobulinemia (IgG <400-500 mg/dL), history of recurrent infections (≥3 events/year), with a target trough IgG level of 600-800 mg/dL, as recommended by the American Academy of Allergy, Asthma, and Immunology 2

Be vigilant for disease transformation, as CLL can rarely transform to more aggressive lymphomas or other hematologic malignancies 5
Consider autoimmune cytopenias, as CLL patients may develop autoimmune phenomena causing cytopenias that respond to corticosteroids rather than CLL-directed therapy, according to the American College of Rheumatology 5